Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep dynamical models of single-cell multiomic velocities predict loss-of-function and rescue perturbations in B cells.

bioRxiv : the preprint server for biology·2026
Same author

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Blood cancer journal·2026
Same author

Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response.

Blood cancer journal·2026
Same author

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Blood·2026
Same author

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Blood advances·2026

Related Experiment Video

Updated: Mar 10, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.7K

General Biomarker Recommendations for Lymphoma.

Lisa Rimsza1, Yuri Fedoriw2, Louis M Staudt2

  • 1Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ (LR), Department of Pathology and Laboratory Medicine, University of North Carolina Medical School, Chapel Hill, NC (YF), Center for Cancer Research, National Cancer Institute, Bethesda, MD (LMS), Department of Medicine, Weill Cornell Medical College, New York, NY (AM), Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, BC, Canada (RG), Clinical Cancer Research Unit, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada (MC), Coordinating Center for Clinical Trials, National Cancer Institute, Bethesda, MD (LB), Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE (KF), Department of Pathology and Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH (ED), Department of Pathology, City of Hope Medical Center, Duarte, CA (JWCC), Biometrics Research Branch, National Cancer Institute, Bethesda, MD (LM), Department of Medicine, Weill Cornell Medicine, New York, NY (JPL), Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK), Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (RFL), Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF), Department of Radiology, Mount Sinai Medical Center New York, NY (LK). rimsza.lisa@mayo.edu.

Journal of the National Cancer Institute
|December 18, 2016
PubMed
Summary
This summary is machine-generated.

Precision oncology is key for diagnosing and treating lymphoid malignancies. National Cancer Institute (NCI) experts met to improve clinical trial design for better lymphoma patient outcomes.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K

Related Experiment Videos

Last Updated: Mar 10, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.7K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • Lymphoid malignancies present diverse clinical and biological behaviors, with increasing prevalence due to treatment advances and indolent tumor types.
  • Accurate prognostic determination at diagnosis remains a challenge for certain lymphoid cancers, like follicular lymphomas.
  • Current diagnostic evaluations are evolving, often requiring initial treatment before prognosis can be reliably assessed.

Purpose of the Study:

  • To outline recommendations from a National Cancer Institute (NCI) meeting for enhancing clinical trial design in lymphoma.
  • To propose strategies for biomarker identification and utilization in NCI-supported lymphoma clinical trials.
  • To address the need for improved diagnostic and prognostic capabilities in lymphoid malignancies.

Main Methods:

  • The content summarizes discussions and recommendations from the NCI clinical trials planning meeting held in November 2014.
  • Focus on strategies for designing clinical trials and developing biomarker proposals for lymphoma research.
  • Incorporation of precision oncology principles to identify specific disease entities and therapeutic targets.

Main Results:

  • The meeting highlighted the critical need for precision oncology to enable specific disease identification and prognostic determination at diagnosis.
  • Refinement of diagnostic evaluations and prognostic assessments is an ongoing scientific endeavor.
  • Clinical trials are essential for evaluating specific disease features and advancing clinical practice for lymphoid malignancies.

Conclusions:

  • Precision oncology offers a path forward for lymphoid malignancies by enabling precise diagnosis, prognosis, and targeted therapies.
  • Advancements in diagnostic evaluation and prognostic determination are crucial for improving patient outcomes.
  • NCI-supported clinical trials and biomarker research are vital for addressing this public health challenge in lymphoma.